The UK and US have concluded a important bilateral deal that will keep zero levies on UK pharmaceutical shipments entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to increase expenditure on medicines through the NHS. This commitment secures that import taxes on these crucial goods will remain at zero for a timeframe of 36 months.
This agreement follows recent threats to dramatically increase import taxes on patented pharmaceutical imports, with increases discussed up to 100%.
"This agreement with the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings much-needed balance to American-British pharmaceutical trade," a release declared.
Trade Significance
Medicines represent one of the UK's biggest exports to the America, which is by far the primary destination for major British pharmaceutical firms.
Export figures show that in the year to the end of September, the UK sold medicines valued at over eleven billion pounds to the US. This figure made up 17.4% of British export trade in that span.
"This deal protects jobs, boosts investment and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement entails several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, repayments exceeded 20%.
Recent Tensions
This agreement takes place against a protracted tension between the drug companies and the ministers over drug pricing and approval rates.
This friction were heightened by assertions that US patients were paying several times more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been paused or scrapped, while substantial investments have been announced toward projects in the United States.
A senior figure acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the past decade.
